E-cadherin expression as a prognostic factor in patients with ovarian cancer: a meta-analysis
Metrics: PDF 1083 views | HTML 1998 views | ?
Chencheng Dai1,2,*, Jian Cao1,3,*, Yu Zeng4, Sujuan Xu4, Xuemei Jia3 and Pengfei Xu1
1Nanjing Maternal and Child Health Institute, Nanjing Maternal and Child Health Care Hospital, Obstetrics and Gynecology Hospital Affiliated to Nanjing Medical University, Nanjing, 210004, China
2The First Clinical Medical College of Nanjing Medical University, Nanjing, 210029, China
3Department of Gynecology, Nanjing Maternal and Child Health Care Hospital, Obstetrics and Gynecology Hospital Affiliated to Nanjing Medical University, Nanjing, 210004, China
4Department of Clinical Laboratory, Nanjing Maternal and Child Health Care Hospital, Obstetrics and Gynecology Hospital Affiliated to Nanjing Medical University, Nanjing, 210004, China
*These authors contributed equally to this work
Pengfei Xu, email: email@example.com
Xuemei Jia, email: firstname.lastname@example.org
Keywords: E-cadherin, ovarian cancer, prognosis, meta-analysis, hazard ratio
Received: February 27, 2017 Accepted: June 12, 2017 Published: June 30, 2017
The prognostic role of epithelial cadherin (E-cadherin) downregulation in ovarian cancer has been assessed for years while the results remain inconclusive. The aim of our study was to assess this issue. Eligible studies were identified through searches of PubMed, EMBASE and Cochrane Database. In total, 1562 patients from 17 studies were included to assess the association between E-cadherin expression and overall survival/progression-free survival and clinicopathological characteristics of ovarian cancer patients. Hazard ratios (HRs) or odds ratios (ORs) with 95% confidence interval (95% CI) were calculated to estimate the effect. The quality of 17 studies was evaluated using the Newcastle Ottawa Quality Assessment Scale. We also performed subgroup analysis, publication bias and sensitivity analysis in this meta-analysis. The results showed that negative E-cadherin expression significantly predicted poor overall survival of ovarian cancer patients (HR = 1.90, 95% CI = 1.50–2.40). However, negative E-cadherin was not associated with poor progression-free survival (HR = 1.19, 95% CI = 0.86–1.64). Moreover, Negative E-cadherin expression was distinctly associated with FIGO stage (OR = 0.42, 95% CI = 0.31–0.57), tumor grade (OR = 0.48, 95% CI = 0.34–0.67), metastasis (OR = 0.13, 95% CI = 0.07–0.26) and recurrence (OR = 0.48, 95% CI = 0.29–0.79). This meta-analysis revealed that negative E-cadherin expression might be a predicative factor of poor prognosis in ovarian cancer patients.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.